These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31039222)

  • 41. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
    Beaumont H; Boeckxstaens GE
    Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proton pump inhibitors: Adverse effects.
    Sataloff RT
    Ear Nose Throat J; 2010 Dec; 89(12):574-6. PubMed ID: 21174271
    [No Abstract]   [Full Text] [Related]  

  • 44. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
    Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
    J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proton pump inhibitors: balancing the benefits and potential fracture risks.
    Richards JB; Goltzman D
    CMAJ; 2008 Aug; 179(4):306-7. PubMed ID: 18695170
    [No Abstract]   [Full Text] [Related]  

  • 47. Letter by Montenegro and Lundberg regarding article, "unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine".
    Montenegro MF; Lundberg JO
    Circulation; 2014 Apr; 129(13):e426. PubMed ID: 24687652
    [No Abstract]   [Full Text] [Related]  

  • 48. The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study.
    Castellani C; Singer G; Kashofer K; Huber-Zeyringer A; Flucher C; Kaiser M; Till H
    Front Cell Infect Microbiol; 2017; 7():444. PubMed ID: 29075620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is there a dark side to long-term proton pump inhibitor therapy?
    Nealis TB; Howden CW
    Am J Ther; 2008; 15(6):536-42. PubMed ID: 19127138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In patients with typical symptoms of GERD and without alarm symptoms, what are the most appropriate dose and duration of empirical PPI therapy that would allow a definitive diagnosis of GERD?].
    Ponce M
    Gastroenterol Hepatol; 2009 Feb; 32(2):126-7. PubMed ID: 19231690
    [No Abstract]   [Full Text] [Related]  

  • 51. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
    Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
    Rheumatology (Oxford); 2017 Feb; 56(2):214-222. PubMed ID: 27179107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Letter by Pinheiro et al regarding article, "unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine".
    Pinheiro LC; Amaral JH; Tanus-Santos JE
    Circulation; 2014 Apr; 129(13):e427. PubMed ID: 24687653
    [No Abstract]   [Full Text] [Related]  

  • 53. Letter by Chyrchel et al regarding article, "unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine".
    Chyrchel B; Chyrchel M; Surdacki A
    Circulation; 2014 Apr; 129(13):e425. PubMed ID: 24687651
    [No Abstract]   [Full Text] [Related]  

  • 54. Response to letters regarding article, "unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine".
    Ghebremariam YT; Lee JC; LePendu P; Erlanson DA; Slaviero A; Shah NH; Leiper JM; Cooke JP
    Circulation; 2014 Apr; 129(13):e428. PubMed ID: 24687654
    [No Abstract]   [Full Text] [Related]  

  • 55. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
    Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
    Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer: multicenter prospective randomized controlled trial.
    Kakushima N; Hori K; Ono H; Horimatsu T; Uedo N; Ohata K; Doyama H; Kaneko K; Oda I; Hikichi T; Kawahara Y; Niimi K; Takaki Y; Mizuno M; Yazumi S; Hosokawa A; Imagawa A; Niimi M; Yoshimura K; Muto M
    J Gastroenterol; 2016 Feb; 51(2):104-11. PubMed ID: 25940151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
    Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
    Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
    Friedlander EA; Pallentino J; Miller SK; VanBeuge SS
    J Am Acad Nurse Pract; 2010 Dec; 22(12):674-83. PubMed ID: 21129076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does treatment with proton pump inhibitors for gastroesophageal reflux disease (GERD) improve asthma symptoms in children with asthma and GERD? A systematic review.
    Sopo SM; Radzik D; Calvani M
    J Investig Allergol Clin Immunol; 2009; 19(1):1-5. PubMed ID: 19274922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.